Zoledronic acid in nine patients with transient osteoporosis of the hip
Transient osteoporosis (TO) is a metabolic bone disorder which causes severe lower extremity pain that exacerbates on weight-bearing . The hip is the most commonly affected joint . In TO, several triggers lead to increased focal bone turnover and bone marrow edema [2, 3]. The gold standard diagnostic exam is magnetic resonance imaging (MRI). Although TO is considered a self-limiting disease, intense symptoms and subsequent functional impairment might last several months and can lead in prolonged immobilization. Moreover, one-third of the patients experience migration to another joint (migratory osteoporosis) [3, 4, 5]. Despite many authors suggest only conservative treatment with analgesics and avoidance of weight-bearing, in many cases, a more targeted pharmacological intervention is used [6, 7, 8, 9]. We aimed to evaluate the effectiveness and safety of zoledronic acid (ZA) infusion in patients with TO of the hip (TOH), as well as the sustainability of the therapeutic...
Compliance with ethical standards
- 5.Evangelatos G, Fragoulis GE, Zampeli E, Kechagia M, Iliopoulos A (2019) Zoledronic acid is effective and safe in migratory osteoporosis. Rheumatology (Oxford). https://doi.org/10.1093/rheumatology/kez345
- 6.Emad Y, Ragab Y, El-Shaarawy N, Rasker JJ (2012) Transient osteoporosis of the hip, complete resolution after treatment with alendronate as observed by MRI description of eight cases and review of the literature. Clin Rheumatol 31:1641–1647. https://doi.org/10.1007/s10067-012-2060-y CrossRefPubMedGoogle Scholar
- 7.Flores-Robles BJ, Sanz-Sanz J, Sanabria-Sanchinel AA, Huntley-Pascual D, Andreu Sanchez JL, Campos Esteban J, Blanco R, Merino-Argumanez C, Espinosa-Malpartida M, Ramos-Giraldez MC, Godoy-Tundidor H, Jimenez-Palop MM, Barbadillo Mateos C, Villa-Alcazar LF, Isasi CM, Mulero JB (2017) Zoledronic acid treatment in primary bone marrow edema syndrome. J Pain Palliat Care Pharmacother 31:52–56. https://doi.org/10.1080/15360288.2016.1276993 CrossRefPubMedGoogle Scholar